A Randomized, Open-label, Single-dose, Two-sequence, Two-period, Cross-over Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of L04TD1 and L04RD1 in Healthy Adult Volunteers
Latest Information Update: 17 Jan 2023
At a glance
- Drugs L04-RD1 (Primary)
- Indications Essential hypertension
- Focus Pharmacokinetics
- Sponsors Celltrion
- 10 Jan 2023 Status changed from active, no longer recruiting to completed.
- 11 Oct 2022 New trial record